Company Encyclopedia
View More
name
Guilin Sanjin
002275.SZ
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache capsule, compound panax notoginseng stomach pain tablets, Sanqi xueshangning capsules, Sanqi xueshangning powder, compound luo han guo qing fei granules, compound luo han guo lung clearing syrup, compound red root tablets, Shuanghu zhongtongning, liver and kidney tonic granules, and jade leaf detoxification granules. Its products are used in various therapeutic areas, such as urinary system disease, oral and throat, cardiovascular and cerebrovascular disease, neurological diseases, respiratory disease, digestive system disease, internal medicine, musculoskeletal system diseases, and tonic drugs.
3.157 T
002275.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking38/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.71%A
    • Profit Margin25.12%A
    • Gross Margin74.12%A
  • Growth ScoreC
    • Revenue YoY-1.56%D
    • Net Profit YoY28.07%B
    • Total Assets YoY9.29%B
    • Net Assets YoY7.66%B
  • Cash ScoreC
    • Cash Flow Margin398.10%C
    • OCF YoY-1.56%D
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreB
    • Gearing Ratio24.53%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Guilin Sanjin released its performance for the first three quarters, with a net profit attributable to the parent company of 385 million yuan, a year-on-year increase of 0.35%

    According to the Zhitong Finance APP, Guilin Sanjin released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.462 billion yuan, a year-on-year decrease of 7.14%. The net profit attributable to shareholders of the listed company was 385 million yuan, a year-on-year increase of 0.35%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 353 million yuan, a year-on-year increase of 1.70%

    Zhitong·
    SZ
    002275
    -0.92%
    Zhitong·
    SZ
    002275
    -0.92%

    Guilin Sanjin plans to distribute 118 million yuan in cash in the first three quarters of 2025

    Guilin Sanjin announced that a board meeting will be held on October 28, 2025, to review the profit distribution plan for the first three quarters of 2025, with a planned cash distribution of 118 million yuan. This plan is based on a net profit of 385 million yuan from January to September 2025, with undistributed profits of 1.635 billion yuan. A cash distribution of 2 yuan will be made for every 10 shares, with no bonus shares or capital increase

    Zhitong·
    SZ
    002275
    -0.92%
    Zhitong·
    SZ
    002275
    -0.92%

    Guilin Sanjin provides an additional guarantee of 20 million yuan for its subsidiary Baochuan Biotechnology

    Guilin Sanjin Pharmaceutical provided a guarantee of 20 million yuan to Baochuan Biotechnology, a wholly-owned subsidiary, to Xiamen International Bank Shanghai Branch, with a guarantee period from August 12, 2025, to August 12, 2028. This guarantee is within the approved guarantee limit of 270 million yuan by the company. After the guarantee, Baochuan Biotechnology's guarantee balance increased to 95.7 million yuan, with a remaining available limit of 20 million yuan

    Zhitong·
    SZ
    002275
    -0.92%
    Zhitong·
    SZ
    002275
    -0.92%

    A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%

    Wallstreetcn·
    SZ
    300158
    -0.30%
    SZ
    002287
    -0.40%
    SH
    600594
    -1.16%
    Wallstreetcn·
    SZ
    300158
    -0.30%
    SZ
    002287
    -0.40%
    SH
    600594
    -1.16%

    The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

    The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit

    Zhitong·
    SZ
    002275
    -0.92%
    SZ
    300199
    +3.00%
    SZ
    300436
    +0.09%
    Zhitong·
    SZ
    002275
    -0.92%
    SZ
    300199
    +3.00%
    SZ
    300436
    +0.09%
    © 2025 Longbridge｜Disclaimer